CMO Cytovance adds 1,000L bioreactor for trial supplies

- Last updated on GMT

CMO Cytovance adds 1,000L bioreactor for trial supplies

Related tags: Biotechnology, Investment

Cytovance Biologics has added a 1,000L bioreactor at its Oklahoma site to support scale-up as clients move through clinical trials.

After receiving investment last year US-based CMO (contract manufacturing organisation) Cytovance strengthened its biologics capabilities by acquiring a site and assets from Genzyme. Installation of a 1,000L bioreactor has now further boosted the CMO’s operations in Oklahoma, US.

The decision to expand our capabilities was made with careful consideration of our clients' needs. The additional state of the art bioreactor will allow Cytovance to provide clinical material to key clients as they move through the clinic​”, Darren Head, president & CEO of Cytovance, said.

Cytovance now has 100L, 500L and 1,000L bioreactors, as well as a 100L wave system and a 100L microbial manufacturing train. Using these tools Cytovance can supply clients with antibodies and recombinant proteins and support development of analytical methods and production processes.

News of the bioreactor comes days after Cytovance bolstered its business development team. Valerie McDonnell, formerly of Althea Technologies, has joined Cytovance as vice president of sales and business development.

Equity investment

In March Great Point Partners invested $22.5m (€17.1m) in Cytovance. The funds allowed Cytovance to move into former Genzyme laboratories and buy bioprocess and analytical equipment from the biotech.

Speaking at the time of the investment Head said Great Point Partners “recognised the potential growth opportunities for Cytovance with additional working capital​”. Addition of a bigger bioreactor continues the growth strategy.

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

Related suppliers

Follow us


View more